triazolam has been researched along with ritonavir in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Blanco, R; Coles, R; Kharasch, ED; Mitchell, D | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Daily, JP; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL | 1 |
| Daily, JP; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Hoffman, JL; Mertzanis, P; Shader, RI; von Moltke, LL | 1 |
| Duan, SX; Durol, AL; Greenblatt, DJ; von Moltke, LL | 1 |
| Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
2 review(s) available for triazolam and ritonavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.
Topics: Acquired Immunodeficiency Syndrome; Alprazolam; Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; HIV Protease Inhibitors; Humans; Hypnotics and Sedatives; Metabolic Clearance Rate; Microsomes, Liver; Oxidoreductases, N-Demethylating; Ritonavir; Triazolam | 1999 |
2 trial(s) available for triazolam and ritonavir
| Article | Year |
|---|---|
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bupropion; Cross-Over Studies; Cytochrome P-450 CYP2B6; Female; HIV Protease Inhibitors; Humans; Liver; Male; Oxidoreductases, N-Demethylating; Ritonavir | 2008 |
Differential impairment of triazolam and zolpidem clearance by ritonavir.
Topics: Adult; Anti-Anxiety Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Half-Life; HIV Protease Inhibitors; HIV Seronegativity; Humans; Hypnotics and Sedatives; Male; Metabolic Clearance Rate; Oxidoreductases, N-Demethylating; Pyridines; Ritonavir; Triazolam; Zolpidem | 2000 |
5 other study(ies) available for triazolam and ritonavir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Furans; Humans; Hydroxylation; Ketoconazole; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides; Triazolam | 2000 |
Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.
Topics: Algorithms; Animals; Anti-Inflammatory Agents; Antibodies, Blocking; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Blotting, Western; Capillaries; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Dexamethasone; Enzyme Induction; Enzyme Inhibitors; GABA Modulators; Gene Expression; HIV Protease Inhibitors; Intestines; Liver; Luminescent Measurements; Male; Microsomes; Oxidoreductases, N-Demethylating; Rats; Rats, Sprague-Dawley; Ritonavir; Triazolam | 2004 |